Compare Novartis AG (NVS) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Target Corporation — how do they compare? Novartis AG trades at $152.55 (market cap $295.37B), while Target Corporation trades at $152.83 (market cap $69.17B). The key difference: Novartis AG is far larger — about 4.3× Target Corporation's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| NVS | TGT | |
|---|---|---|
Market Cap | $295.37B | $69.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $152.35 |
52-Week Low | $119.31 | $83.68 |
Enterprise Value | $336.69B | $84.47B |
Dividend Yield | 3.07% | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.
The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.
Target Corporation (TGT) trades at $152.85, up 0.5% today, near its 52-week high. The stock shows strong momentum with bullish technical signals and consistent earnings beats in recent quarters. Revenue remains stable around $106 billion, with a net income margin of 3.24% and solid cash flow from operations of $7.37 billion in 2025. Recent news includes the appointment of a chief AI officer, highlighting strategic focus on technology.
The outlook is positive with analyst consensus leaning buy, though valuation multiples like P/E of 20.12 suggest fair pricing. Risks include competitive retail pressures and macroeconomic sensitivity. Upside potential exists if AI initiatives drive efficiency, but investors should monitor Q2 2026 earnings for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
